Mirvetuximab soravtansine for advanced, epithelial ovarian, fallopian tube, or primary peritoneal cancer with high folate receptor-alpha expression

Mirvetuximab soravtansine is in clinical development for the treatment of adults with advanced, platinum-resistant, high-grade epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer with high folate receptor-alpha expression. Epithelial ovarian cancer means the cancer started in the surface layer covering the ovary. The main symptoms are frequent swollen or bloated tummy, pain or tenderness in the stomach, loss of appetite and an urgent need to urinate. Symptoms can go unnoticed, so the cancer can be diagnosed when the disease is advanced and challenging to treat. Most patients have the cancer removed surgically and receive chemotherapy, which usually includes platinum-based drugs. However, the disease often recurs, and platinum-based chemotherapy drugs may be less effective. If the cancer recurs within 6 months of the previous treatment, and platinum-based chemotherapy does not work, the disease is called “platinum-resistant”.